CA
NZ
UK
AU
IND
US
• Veradermics is down a fractional 0.22% intraday at $117.03, effectively unchanged with very light volume and no new company-specific announcement.
• IceCure Medical is down 20.43% intraday at $7.40 with heavy selling from the open and no meaningful recovery bounce, suggesting simultaneous exit by weaker holders.
• ICON plc is up 5.11% intraday at $166.26, having risen from near $138 in early June, with dip buyers consistently active on any weakness signalling strong institutional conviction.
• InMode is up approximately 11% intraday at $14.83 after receiving a take-private proposal at $16.20 per share from M.N. Business Strategy, which includes co-founder and CEO Moshe Mizrahy.
• Medpace Holdings is up 2.62% intraday at $526.21, with the gain measured and steady, consistent with institutional CRO sector positioning.
• Monopar Therapeutics is up 2.47% intraday at $91.19 with the gain steady and without violent spikes, suggesting low-level accumulation rather than speculative momentum chasing.
• Myriad Genetics is up 4.60% intraday at $5.46 with the gain sustained through the session, suggesting the M&A re-rating is doing genuine work rather than producing a fleeting spike.
• Natera is trading between $258.50 and $271.23 intraday, hitting a 52-week high of $271.23 on two confirmed catalysts announced today and yesterday.
• NeoGenomics is up 5.04% intraday at $13.55, holding near session highs in a technically constructive pattern against prior resistance around $13 to $14.
• Definium Therapeutics is trading at $44.15, up 4.79% intraday, peaking near $44.54 as investors digest the landmark Phase 3 MDD readout announced on June 22, 2026.
Please wait processing your request...